Drug intelligence / Profile preview

FINCoVac 2.0

Development stage: Unknown
Lead developer: Rokote Laboratories
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

**FINCoVac 2.0** is a second-generation intranasal COVID-19 vaccine developed by Rokote Laboratories Finland Ltd. It employs **adenoviral vector gene transfer technology** to deliver genetic material encoding a modified SARS-CoV-2 spike protein, programming nasopharyngeal cells to produce the antigen and induce a strong mucosal immune response. Designed to target critical SARS-CoV-2 variants, it serves as an easy-to-administer booster for previously vaccinated individuals, aiming to prevent both infection and transmission.[1][2][5][12]

Other names: FINCOVAC 2.0FINCOVAC2.0FINCOVAC-2.0

Targets

CD46 (CD46 Molecule)

Beyond the preview

Go deeper on FINCoVac 2.0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FINCoVac 2.0.

Explore the full profile